<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Emerg Infect Dis</journal-id>
      <journal-id journal-id-type="publisher-id">EID</journal-id>
      <journal-title-group>
        <journal-title>Emerging Infectious Diseases</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1080-6040</issn>
      <issn pub-type="epub">1080-6059</issn>
      <publisher>
        <publisher-name>Centers for Disease Control and Prevention</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">19523302</article-id>
      <article-id pub-id-type="pmc">2727307</article-id>
      <article-id pub-id-type="publisher-id">09-0101</article-id>
      <article-id pub-id-type="doi">10.3201/eid1506.090101</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Dispatch</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Leishmaniasis, Autoimmune Rheumatic Disease, and
                    Anti&#x2013;Tumor Necrosis Factor Therapy, Europe</article-title>
        <alt-title alt-title-type="running-head">Leishmaniasis and Anti-TNF Therapy,
                Europe</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Xynos</surname>
            <given-names>Ioannis D.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tektonidou</surname>
            <given-names>Maria G.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pikazis</surname>
            <given-names>Dimitrios</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Sipsas</surname>
            <given-names>Nikolaos V.</given-names>
          </name>
        </contrib>
        <aff id="aff1">National and Kapodistrian University of Athens, Athens, Greece (I.D.
                    Xynos, D. Pikazis, N.V. Sipsas)</aff>
        <aff id="aff2">Euroclinic Hospital of Athens, Athens (M.G. Tektonidou)</aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1">Address for correspondence: Nikolaos V. Sipsas, Pathophysiology
                    Department, Athens University Medical School, Mikras Asias 75, Athens, 11527,
                    Greece; email: <email xlink:href="nsipsas@med.uoa.gr">nsipsas@med.uoa.gr</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>6</month>
        <year>2009</year>
      </pub-date>
      <volume>15</volume>
      <issue>6</issue>
      <fpage>956</fpage>
      <lpage>959</lpage>
      <abstract>
        <p>We report 2 cases of leishmaniasis in patients with autoimmune rheumatic diseases
                    in Greece. To assess trends in leishmaniasis reporting in this patient
                    population, we searched the literature for similar reports from Europe. Reports
                    increased during 2004&#x2013;2008, especially for patients treated with
                    anti&#x2013;tumor necrosis factor agents.</p>
      </abstract>
      <kwd-group kwd-group-type="author">
        <title>Keywords: </title>
        <kwd>Anti-TNF</kwd>
        <kwd>tumor necrosis factor</kwd>
        <kwd>leishmaniasis</kwd>
        <kwd>rheumatic disease</kwd>
        <kwd>autoimmune diseases</kwd>
        <kwd>parasites</kwd>
        <kwd>Europe</kwd>
        <kwd>dispatch</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p>We report 2 new cases of leishmaniasis involving patients with autoimmune rheumatic
            diseases who received anti&#x2013;tumor necrosis factor (anti-TNF) agents. We also
            reviewed all similar cases from Europe reported in the literature, and we discuss the
            implications of leishmaniasis in the setting of anti-TNF therapy, which is associated
            with increased risk for opportunistic infections (<xref ref-type="bibr" rid="R1"><italic>1</italic></xref>).</p>
    <sec sec-type="other1">
      <title>The Study</title>
      <p>Patient 1, a 55-year-old man who had received a diagnosis of ankylosing spondylitis 7
                years previously, was admitted to Laikon Hosptal, Athens, Greece, in May 2005 for
                evaluation of encrusted vesicular lesions on the face. The lesions were painless but
                mildly pruritic. The patient had been receiving nonsteroidal antiinflammatory agents
                until 12 months before admission, when his medications were changed to infliximab (3
                mg/kg) plus methotrexate (10 mg weekly) because of his deteriorating clinical
                condition. He was living in a leishmaniasis-endemic area in Athens, had no pets in
                his house, and had no history of recent travel abroad. The central scale was removed
                from one of the lesions, and scrapings from the base of the lesion were stained with
                Giemsa stain, which showed intracellular amastigotes with peripheral nuclei and
                rod-shaped kinetoplasts. Results of indirect immunoflorescent antibody (IFA) testing
                were positive for <italic>Leishmania</italic> parasites (titer 6,400). Infliximab
                and methotrexate therapy was discontinued, and treatment with liposomal amphotericin
                B was started at a dose of 3 mg/kg, for days 1 to 5, and 2 additional doses (3
                mg/kg) on days 14 and 21. Eighteen months later, treatment with etanercept was begun
                due to the patient&#x2019;s severe spondyloarthritis; 2 years after the new
                anti-TNF treatment, he is well, with no signs or symptoms of leishmaniasis.</p>
      <p>Patient 2, a 71-year-old woman who had giant cell arteritis, was admitted to the
                Euroclinic Hospital, Athens, in May 2005 with a high fever and fatigue. The patient
                had been treated with infliximab (0.25 mg/kg) and variable doses of
                methylprednisolone for the previous 2 years. Methotrexate (10 mg/week) was added 1
                year before admission. She was also living in an Athens suburb, which is
                leishmaniasis-endemic, and had 4 dogs. Laboratory tests showed a high level of
                C-reactive protein (163 mg/L, reference range 0&#x2013;6 mg/L), high erythrocyte
                sedimentation rate (77 mm/h), pancytopenia (hemoglobin level 12.5 g/dL, leukocyte
                count 3,300/mm<sup>3</sup>, platelet count 122,000/ mm<sup>3</sup>), and diffuse
                hyperglobulinemia. The examination of Giemsa-stained smears from bone marrow
                aspirate demonstrated abundant <italic>Leishmania</italic> parasites, and IFA was
                marginally positive for <italic>Leishmania</italic> antibodies (titer 400). PCR was
                positive for the detection of the <italic>Leishmania</italic> genome in peripheral
                blood. Infliximab and methotrexate treatment was discontinued, and treatment with
                intravenous liposomal amphotericin B was started at a dose of 3 mg/kg for 5 days.
                Two days later, the fever subsided, and within the next few days, the patient
                recovered from pancytopenia, while the inflammatory markers showed a gradual
                decrease. She received 2 additional doses of liposomal amphotericin B (3 mg/kg) on
                days 7 and 14, and by that time, she exhibited no signs or symptoms of visceral
                leishmaniasis.</p>
      <p>We then searched Medline, EMBASE, and Current Contents databases for all reports on
                leishmaniasis in Europe and the Mediterranean area among patients with autoimmune
                rheumatic diseases, which are often treated with anti-TNF agents. In our search
                strategy, we used medical subject heading terms and text words, including rheumatoid
                arthritis, juvenile rheumatoid arthritis, Still&#x2019;s disease, seronegative
                arthritis, psoriatic arthritis, Beh&#xE7;et&#x2019;s disease, ankylosing
                spondylitis, reactive arthritis, vasculitis, giant cell arteritis,
                Wegener&#x2019;s granulomatosis (ANCA [anti-neutrophil cytoplasmic
                antibody]&#x2013;associated vasculitis), panarteritis nodosa, leishmaniasis,
                    <italic>Leishmania</italic>, and anti-TNF. We searched the reference list of
                each resulting report for additional publications. We used no language or time
                restrictions.</p>
      <p>All retrieved articles were case reports. We found 13 additional cases of
                leishmaniasis in patients with autoimmune rheumatic diseases (<xref ref-type="bibr" rid="R2"><italic>2</italic></xref>&#x2013;<xref ref-type="bibr" rid="R14"><italic>14</italic></xref>), all published after the introduction of anti-TNF agents in 1998 (<xref ref-type="table" rid="T1">Table</xref>). All 15 patients (including our 2
                patients) were treated in the past or at the time of the diagnosis of leishmaniasis
                with <underline>&gt;</underline>1 standard immunosuppressive agents, including
                corticosteroids (11/14 [78.5%]) patients for whom treatment details were reported),
                methotrexate (9/14 [64.3%]), cyclosporine (3/14 [21.4%]), cyclophosphamide (3/14
                [21.4%]), azathioprine (2/14 [14.3]), and chlorambucil (1/14 [7.1%]). Seven (46.6%)
                patients received an anti-TNF agent along with standard immunosuppressive agents.
                Two of the 15 reported patients had been treated with a recombinant
                interleukin&#x2013;1 receptor antagonist (anakinra; Amgen Inc., Thousand Oaks,
                CA, USA) (<xref ref-type="bibr" rid="R5"><italic>5</italic></xref>,<xref ref-type="bibr" rid="R13"><italic>13</italic></xref>). In most of the patients, visceral leishmaniasis developed (13 patients,
                86.6%), while cutaneous leishmaniasis developed in 2 patients (1 was receiving an
                anti-TNF agent). All patients were living in leishmaniasis-endemic areas of Europe
                    (<xref ref-type="fig" rid="F1">Figure</xref>).</p>
      <table-wrap id="T1" position="float">
        <label>Table</label>
        <caption>
          <title>Detailed characteristics of 15 patients with autoimmune rheumatic
                        disorders in whom leishmaniasis developed, Europe*</title>
        </caption>
        <table frame="hsides" rules="groups">
          <col width="32" span="1"/>
          <col width="35" span="1"/>
          <col width="35" span="1"/>
          <col width="53" span="1"/>
          <col width="53" span="1"/>
          <col width="40" span="1"/>
          <col width="11" span="1"/>
          <col width="94" span="1"/>
          <col width="47" span="1"/>
          <col width="47" span="1"/>
          <col width="29" span="1"/>
          <thead>
            <tr>
              <th rowspan="2" valign="top" align="left" scope="col" colspan="1">Patient no.</th>
              <th rowspan="2" valign="top" align="center" scope="col" colspan="1">Country</th>
              <th rowspan="2" valign="top" align="center" scope="col" colspan="1">Age, y/sex</th>
              <th rowspan="2" valign="top" align="center" scope="col" colspan="1">Disease</th>
              <th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1">Anti-TNF
                                treatment</th>
              <th rowspan="2" valign="top" align="left" scope="col" colspan="1"/>
              <th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1">Other
                                immunosuppressive treatments</th>
              <th rowspan="2" valign="top" align="center" scope="col" colspan="1">Form
                                    of&#x2028;<italic>Leishmania</italic>&#x2028;infection</th>
              <th rowspan="2" valign="top" align="center" scope="col" colspan="1">Ref.</th>
            </tr>
            <tr>
              <th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">Agent</th>
              <th valign="top" align="center" scope="col" rowspan="1" colspan="1">Duration, mo</th>
              <th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">Agent(s)</th>
              <th valign="top" align="center" scope="col" rowspan="1" colspan="1">Duration, mo</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td valign="top" align="left" scope="row" rowspan="1" colspan="1">1</td>
              <td valign="top" align="center" rowspan="1" colspan="1">France</td>
              <td valign="top" align="center" rowspan="1" colspan="1">66/M</td>
              <td valign="top" align="center" rowspan="1" colspan="1">ANCA-associated vasculitis</td>
              <td valign="top" align="center" rowspan="1" colspan="1">NA</td>
              <td valign="top" align="center" rowspan="1" colspan="1">NA</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="center" rowspan="1" colspan="1">Cyclophosphamide, methotrexate,
                                corticosteroids</td>
              <td valign="top" align="center" rowspan="1" colspan="1">120</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Visceral</td>
              <td valign="top" align="center" rowspan="1" colspan="1"> (<xref ref-type="bibr" rid="R7"><italic>7</italic></xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" scope="row" rowspan="1" colspan="1">2</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Israel</td>
              <td valign="top" align="center" rowspan="1" colspan="1">56/M</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Rheumatoid arthritis</td>
              <td valign="top" align="center" rowspan="1" colspan="1">NA</td>
              <td valign="top" align="center" rowspan="1" colspan="1">NA</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="center" rowspan="1" colspan="1">Methotrexate, corticosteroids</td>
              <td valign="top" align="center" rowspan="1" colspan="1">120</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Cutaneous</td>
              <td valign="top" align="center" rowspan="1" colspan="1"> (<xref ref-type="bibr" rid="R8"><italic>8</italic></xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" scope="row" rowspan="1" colspan="1">3</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Italy</td>
              <td valign="top" align="center" rowspan="1" colspan="1">35/M</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Beh&#xE7;et disease</td>
              <td valign="top" align="center" rowspan="1" colspan="1">NA</td>
              <td valign="top" align="center" rowspan="1" colspan="1">NA</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="center" rowspan="1" colspan="1">Chlorambucil, corticosteroids</td>
              <td valign="top" align="center" rowspan="1" colspan="1">36</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Visceral</td>
              <td valign="top" align="center" rowspan="1" colspan="1"> (<xref ref-type="bibr" rid="R9"><italic>9</italic></xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" scope="row" rowspan="1" colspan="1">4</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Spain</td>
              <td valign="top" align="center" rowspan="1" colspan="1">50/M</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Rheumatoid arthritis</td>
              <td valign="top" align="center" rowspan="1" colspan="1">NA</td>
              <td valign="top" align="center" rowspan="1" colspan="1">NA</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="center" rowspan="1" colspan="1">Methotrexate, corticosteroids</td>
              <td valign="top" align="center" rowspan="1" colspan="1">120</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Visceral</td>
              <td valign="top" align="center" rowspan="1" colspan="1">(10)</td>
            </tr>
            <tr>
              <td valign="top" align="left" scope="row" rowspan="1" colspan="1">5</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Italy</td>
              <td valign="top" align="center" rowspan="1" colspan="1">60/M</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Polyarteritis nodosa</td>
              <td valign="top" align="center" rowspan="1" colspan="1">NA</td>
              <td valign="top" align="center" rowspan="1" colspan="1">NA</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="center" rowspan="1" colspan="1">Cyclophosphamide, corticosteroids</td>
              <td valign="top" align="center" rowspan="1" colspan="1">2</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Visceral</td>
              <td valign="top" align="center" rowspan="1" colspan="1"> (<xref ref-type="bibr" rid="R11"><italic>11</italic></xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" scope="row" rowspan="1" colspan="1">6</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Spain</td>
              <td valign="top" align="center" rowspan="1" colspan="1">55/M</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Psoriatic arthritis</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Infliximab</td>
              <td valign="top" align="center" rowspan="1" colspan="1">9</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="center" rowspan="1" colspan="1">No details given</td>
              <td valign="top" align="center" rowspan="1" colspan="1">300</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Visceral</td>
              <td valign="top" align="center" rowspan="1" colspan="1"> (<xref ref-type="bibr" rid="R2"><italic>2</italic></xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" scope="row" rowspan="1" colspan="1">7</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Italy</td>
              <td valign="top" align="center" rowspan="1" colspan="1">76/M</td>
              <td valign="top" align="center" rowspan="1" colspan="1">ANCA-associated vasculitis</td>
              <td valign="top" align="center" rowspan="1" colspan="1">NA</td>
              <td valign="top" align="center" rowspan="1" colspan="1">NA</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="center" rowspan="1" colspan="1">Cyclophosphamide, corticosteroids</td>
              <td valign="top" align="center" rowspan="1" colspan="1">36</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Visceral</td>
              <td valign="top" align="center" rowspan="1" colspan="1"> (<xref ref-type="bibr" rid="R12"><italic>12</italic></xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" scope="row" rowspan="1" colspan="1">8</td>
              <td valign="top" align="center" rowspan="1" colspan="1">France</td>
              <td valign="top" align="center" rowspan="1" colspan="1">53/F</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Rheumatoid arthritis</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Infliximab</td>
              <td valign="top" align="center" rowspan="1" colspan="1">12</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="center" rowspan="1" colspan="1">Azathioprine, corticosteroids</td>
              <td valign="top" align="center" rowspan="1" colspan="1">12</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Visceral</td>
              <td valign="top" align="center" rowspan="1" colspan="1"> (<xref ref-type="bibr" rid="R3"><italic>3</italic></xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" scope="row" rowspan="1" colspan="1">9</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Italy</td>
              <td valign="top" align="center" rowspan="1" colspan="1">69/F</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Rheumatoid arthritis</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Adalimumab</td>
              <td valign="top" align="center" rowspan="1" colspan="1">25</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="center" rowspan="1" colspan="1">Methotrexate, corticosteroids</td>
              <td valign="top" align="center" rowspan="1" colspan="1">360</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Visceral</td>
              <td valign="top" align="center" rowspan="1" colspan="1"> (<xref ref-type="bibr" rid="R4"><italic>4</italic></xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" scope="row" rowspan="1" colspan="1">10</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Greece</td>
              <td valign="top" align="center" rowspan="1" colspan="1">60/F</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Rheumatoid arthritis</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Etanercept</td>
              <td valign="top" align="center" rowspan="1" colspan="1">18&#x2020;</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="center" rowspan="1" colspan="1">Cyclosporine, corticosteroids, anakinra</td>
              <td valign="top" align="center" rowspan="1" colspan="1">96</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Visceral</td>
              <td valign="top" align="center" rowspan="1" colspan="1"> (<xref ref-type="bibr" rid="R5"><italic>5</italic></xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" scope="row" rowspan="1" colspan="1">11</td>
              <td valign="top" align="center" rowspan="1" colspan="1">France</td>
              <td valign="top" align="center" rowspan="1" colspan="1">9/F</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Juvenile rheumatoid arthritis</td>
              <td valign="top" align="center" rowspan="1" colspan="1">NA</td>
              <td valign="top" align="center" rowspan="1" colspan="1">NA</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="center" rowspan="1" colspan="1">Cyclosporine, methotrexate,
                                corticosteroids, anakinra</td>
              <td valign="top" align="center" rowspan="1" colspan="1">60</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Visceral</td>
              <td valign="top" align="center" rowspan="1" colspan="1"> (<xref ref-type="bibr" rid="R13"><italic>13</italic></xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" scope="row" rowspan="1" colspan="1">12</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Greece</td>
              <td valign="top" align="center" rowspan="1" colspan="1">45/M</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Psoriatic arthritis</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Infliximab</td>
              <td valign="top" align="center" rowspan="1" colspan="1">60</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="center" rowspan="1" colspan="1">Methotrexate, corticosteroids</td>
              <td valign="top" align="center" rowspan="1" colspan="1">60</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Visceral</td>
              <td valign="top" align="center" rowspan="1" colspan="1"> (<xref ref-type="bibr" rid="R6"><italic>6</italic></xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" scope="row" rowspan="1" colspan="1">13</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Greece</td>
              <td valign="top" align="center" rowspan="1" colspan="1">65/F</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Rheumatoid arthritis</td>
              <td valign="top" align="center" rowspan="1" colspan="1">NA</td>
              <td valign="top" align="center" rowspan="1" colspan="1">NA</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="center" rowspan="1" colspan="1">Methotrexate</td>
              <td valign="top" align="center" rowspan="1" colspan="1">96</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Visceral</td>
              <td valign="top" align="center" rowspan="1" colspan="1"> (<xref ref-type="bibr" rid="R14"><italic>14</italic></xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" scope="row" rowspan="1" colspan="1">14</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Greece</td>
              <td valign="top" align="center" rowspan="1" colspan="1">71/F</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Giant cell arteritis</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Infliximab</td>
              <td valign="top" align="center" rowspan="1" colspan="1">24</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="center" rowspan="1" colspan="1">Methotrexate, corticosteroids</td>
              <td valign="top" align="center" rowspan="1" colspan="1">24</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Visceral</td>
              <td valign="top" align="center" rowspan="1" colspan="1">This study</td>
            </tr>
            <tr>
              <td valign="top" align="left" scope="row" rowspan="1" colspan="1">15</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Greece</td>
              <td valign="top" align="center" rowspan="1" colspan="1">55/M</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Ankylosing spondylitis</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Infliximab</td>
              <td valign="top" align="center" rowspan="1" colspan="1">12</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="center" rowspan="1" colspan="1">Methotrexate</td>
              <td valign="top" align="center" rowspan="1" colspan="1">12</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Cutaneous</td>
              <td valign="top" align="center" rowspan="1" colspan="1">This study</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <p>*TNF, tumor necrosis factor; Ref., reference; ANCA, anti-neutrophil
                        cytoplasmic antibody; NA, not applicable.&#x2028;&#x2020;All
                        biologic treatments had been terminated 6 mo before leishmaniasis
                    occurred.</p>
        </table-wrap-foot>
      </table-wrap>
      <fig id="F1" fig-type="figure" position="float">
        <label>Figure</label>
        <caption>
          <p>Reported cases of leishmaniasis in patients with autoimmune rheumatic
                        diseases in Europe, indicated by stars (1 case from Israel not shown). Dark
                        gray shading, distribution of leishmaniasis; light gray shading,
                        distribution of leishmaniasis vector sandfly. Source: World Health
                        Organization, 2004 (<ext-link ext-link-type="uri" xlink:href="http://www.who.int/tdr/svc/publications/tdr-research-publications/swg-report-leishmaniasis">www.who.int/tdr/svc/publications/tdr-research-publications/swg-report-leishmaniasis</ext-link>).</p>
        </caption>
        <graphic xlink:href="09-0101-F"/>
      </fig>
      <p>The anti-TNF agents were introduced into clinical practice in 1998, and the first
                case of leishmaniasis associated with anti-TNF blockade occurred in 2001 (<xref ref-type="bibr" rid="R4"><italic>4</italic></xref>). During the 6-year period (1998&#x2013;2003), a total of 6 reports were
                made of leishmaniasis in patients with rheumatic diseases; 1 (16.6%) occurred in a
                patient treated with an anti-TNF agent. During the ensuing 5 years
                (2004&#x2013;2008), 9 cases of leishmaniasis were reported, 6 (66.6%) in
                patients receiving anti-TNF agents.</p>
      <p>The median duration of previous immunosuppressive therapy, before the diagnosis of
                leishmaniasis, was 60 months (range 2&#x2013;360 months) for all 15 patients
                (&#x3A4;able). For the 7 patients who received anti-TNF agents, the median
                duration of anti-TNF treatment was 18 months (range 9&#x2013;60 months). Six of
                these 7 patients were receiving anti-TNF agents when symptoms and signs of
                leishmaniasis occurred. In 1 patient (<xref ref-type="bibr" rid="R5"><italic>5</italic></xref>), biologic treatments had been discontinued 6 months before the diagnosis of
                leishmaniasis (<xref ref-type="table" rid="T1">Table</xref>). Only 1 patient had
                been tested for antibodies against <italic>Leishmania</italic> spp. before
                immunosuppressive therapy was begun, and the results were negative (<xref ref-type="bibr" rid="R6"><italic>6</italic></xref>). Therefore, this is the only case with compelling evidence that
                leishmaniasis was a primary infection and not reactivation of a latent
            infection.</p>
    </sec>
    <sec sec-type="conclusions">
      <title>Conclusions</title>
      <p>Our data suggest that the introduction of TNF blockade into the clinical practice is
                associated with increasing reports of leishmaniasis in patients with autoimmune
                rheumatic diseases who live in leishmaniasis-endemic areas of Europe. Notably, in
                most reported cases, patients had not received anti-TNF agents but other
                immunosuppressants. However, all cases of leishmaniasis in patients with autoimmune
                rheumatic diseases were reported after 1998, the year of introduction of anti-TNF
                agents, and most (9/15) of the reported leishmaniasis cases occurred during the past
                5 years (2004&#x2013;2008), mainly among patients receiving anti-TNF agents (6
                of the 9 patients with leishmaniasis; 66.6%). This increase coincides with the
                increasing use of anti-TNF agents during the same period, as prescription practice
                started changing toward treating patients with lower disease activity (<xref ref-type="bibr" rid="R15"><italic>15</italic></xref>). Another indirect piece of evidence that TNF blockade may increase the risk
                for leishmaniasis is that the median duration of previous anti-TNF treatment before
                the diagnosis of leishmaniasis was significantly shorter than the median duration of
                immunosuppressive therapy for all 15 patients (18 vs. 60 months).</p>
      <p>Our report has limitations. It is unclear for all cases (with 1 exception) presented
                in this article whether leishmaniasis was primary infection or reactivation of
                latent disease. We cannot also exclude the possibility that the concomitant,
                long-term use of other immunosuppressants, and not the anti-TNF agents per se,
                played a crucial role in the development of leishmaniasis. Different prescribing
                patterns of anti-TNF agents might influence the number of cases reported from each
                disease-endemic European country. However, the small number of reported cases and
                the lack of data on differences in the anti-TNF prescribing policies do not allow
                any conclusions to be reached. Finally, due to underreporting, the reported cases
                may underestimate the real incidence of leishmaniasis among patients with autoimmune
                rheumatic diseases.</p>
      <p>Prospective studies to estimate the incidence of the disease, the impact of risk
                factors and the need for serologic screening for leishmaniasis before initiation of
                anti-TNF agents or any other immunosuppressive treatment are clearly needed. This is
                particularly important since currently only a few patients with autoimmune rheumatic
                diseases receive anti-TNF agents (<xref ref-type="bibr" rid="R15"><italic>15</italic></xref>). Therefore, the use of anti-TNF treatment is likely going to increase,
                possibly causing a parallel increase in opportunistic infections such as
                leishmaniasis.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="citation">
        <p><italic>Suggested citation for this article</italic>: Xynos ID, Tektonidou MG,
                    Pikazis D, Sipsas NV. Leishmaniasis, autoimmune rheumatic disease, and
                    anti&#x2013;tumor necrosis factor therapy, Europe. Emerg Infect Dis [serial
                    on the Internet]. 2009 Jun [<italic>date cited</italic>]. Available from
                        <ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/EID/content/15/6/956.htm">http://www.cdc.gov/EID/content/15/6/956.htm</ext-link></p>
      </fn>
    </fn-group>
    <ack>
      <p>N.V.S. received support from the Special Account for Research Funds of the National
                and Kapodistrian University of Athens, Greece.</p>
    </ack>
    <bio>
      <p>Dr Xynos is a senior resident in General Internal Medicine at Laikon General Hospital
                in Athens, Greece, and is affiliated with the Infectious Diseases Unit, Department
                of Pathophysiology, University of Athens Medical School. His research interests
                include the study of infections in patients with autoimmune rheumatic diseases.</p>
    </bio>
    <ref-list>
      <title>References</title>
      <ref id="R1">
        <label>1. </label>
        <mixed-citation publication-type="journal"><string-name>
                        <surname>Winthrop</surname>
                        <given-names>KL</given-names>
                    </string-name> <article-title>Risk and prevention of tuberculosis and other
                        serious opportunistic infections associated with tumor necrosis factor.</article-title><source>Nat Clin Pract Rheumatol</source>
                        <year>2006</year>;<volume>2</volume>:<fpage>602</fpage>&#x2013;<lpage>10</lpage>
                        <pub-id pub-id-type="doi">10.1038/ncprheum0336</pub-id><pub-id pub-id-type="pmid">17075599</pub-id></mixed-citation>
      </ref>
      <ref id="R2">
        <label>2. </label>
        <mixed-citation publication-type="journal"><string-name>
                        <surname>Romani-Costa</surname>
                        <given-names>V</given-names>
                    </string-name>, <string-name>
                        <surname>Sanchez</surname>
                        <given-names>C</given-names>
                    </string-name>, <string-name>
                        <surname>Moya</surname>
                        <given-names>F</given-names>
                    </string-name>, <string-name>
                        <surname>Estany</surname>
                        <given-names>C</given-names>
                    </string-name> <article-title>Visceral leishmaniasis related to infliximab
                        administration.</article-title><source>Enferm Infecc Microbiol Clin</source>
                        <year>2004</year>;<volume>22</volume>:<fpage>310</fpage> <pub-id pub-id-type="doi">10.1157/13059832</pub-id><pub-id pub-id-type="pmid">15207130</pub-id></mixed-citation>
      </ref>
      <ref id="R3">
        <label>3. </label>
        <mixed-citation publication-type="journal"><string-name>
                        <surname>Fabre</surname>
                        <given-names>S</given-names>
                    </string-name>, <string-name>
                        <surname>Gibert</surname>
                        <given-names>C</given-names>
                    </string-name>, <string-name>
                        <surname>Lechiche</surname>
                        <given-names>C</given-names>
                    </string-name>, <string-name>
                        <surname>Dereure</surname>
                        <given-names>J</given-names>
                    </string-name>, <string-name>
                        <surname>Jorgesen</surname>
                        <given-names>C</given-names>
                    </string-name>, <string-name>
                        <surname>Sany</surname>
                        <given-names>J</given-names>
                    </string-name> <article-title>Visceral leishmaniasis infection in a rheumatoid
                        arthritis patient treated with infliximab.</article-title><source>Clin Exp Rheumatol</source>
                        <year>2005</year>;<volume>23</volume>:<fpage>891</fpage>&#x2013;<lpage>2</lpage><pub-id pub-id-type="pmid">16396712</pub-id></mixed-citation>
      </ref>
      <ref id="R4">
        <label>4. </label>
        <mixed-citation publication-type="journal"><string-name>
                        <surname>Bassetti</surname>
                        <given-names>M</given-names>
                    </string-name>, <string-name>
                        <surname>Pizzorni</surname>
                        <given-names>C</given-names>
                    </string-name>, <string-name>
                        <surname>Gradoni</surname>
                        <given-names>L</given-names>
                    </string-name>, <string-name>
                        <surname>Del Bono</surname>
                        <given-names>V</given-names>
                    </string-name>, <string-name>
                        <surname>Cutolo</surname>
                        <given-names>M</given-names>
                    </string-name>, <string-name>
                        <surname>Viscoli</surname>
                        <given-names>C</given-names>
                    </string-name> <article-title>Visceral leishmaniasis infection in a rheumatoid
                        arthritis patient treated with adalimumab.</article-title><source>Rheumatology</source>
                        <year>2006</year>;<volume>45</volume>:<fpage>1446</fpage>&#x2013;<lpage>8</lpage>
                        <pub-id pub-id-type="doi">10.1093/rheumatology/kel235</pub-id><pub-id pub-id-type="pmid">16887847</pub-id></mixed-citation>
      </ref>
      <ref id="R5">
        <label>5. </label>
        <mixed-citation publication-type="journal"><string-name>
                        <surname>Bagalas</surname>
                        <given-names>V</given-names>
                    </string-name>, <string-name>
                        <surname>Kioumis</surname>
                        <given-names>I</given-names>
                    </string-name>, <string-name>
                        <surname>Argyropoulou</surname>
                        <given-names>P</given-names>
                    </string-name>, <string-name>
                        <surname>Patakas</surname>
                        <given-names>D</given-names>
                    </string-name> <article-title>Visceral leishmaniasis infection in a patient
                        with rheumatoid arthritis treated with etanercept.</article-title><source>Clin Rheumatol</source>
                        <year>2007</year>;<volume>26</volume>:<fpage>1344</fpage>&#x2013;<lpage>5</lpage>
                        <pub-id pub-id-type="doi">10.1007/s10067-006-0356-5</pub-id><pub-id pub-id-type="pmid">16865310</pub-id></mixed-citation>
      </ref>
      <ref id="R6">
        <label>6. </label>
        <mixed-citation publication-type="journal"><string-name>
                        <surname>Tektonidou</surname>
                        <given-names>MG</given-names>
                    </string-name>, <string-name>
                        <surname>Skopouli</surname>
                        <given-names>FN</given-names>
                    </string-name> <article-title>Visceral leishmaniasis in a patient with
                        psoriatic arthritis treated with infliximab: reactivation of a latent
                        infection?</article-title><source>Clin Rheumatol</source>
                        <year>2008</year>;<volume>27</volume>:<fpage>541</fpage>&#x2013;<lpage>2</lpage>
                        <pub-id pub-id-type="doi">10.1007/s10067-007-0775-y</pub-id><pub-id pub-id-type="pmid">17963018</pub-id></mixed-citation>
      </ref>
      <ref id="R7">
        <label>7. </label>
        <mixed-citation publication-type="journal"><string-name>
                        <surname>Zanaldi</surname>
                        <given-names>H</given-names>
                    </string-name>, <string-name>
                        <surname>Rosenthal</surname>
                        <given-names>E</given-names>
                    </string-name>, <string-name>
                        <surname>Marty</surname>
                        <given-names>P</given-names>
                    </string-name>, <string-name>
                        <surname>Chichmanian</surname>
                        <given-names>RM</given-names>
                    </string-name>, <string-name>
                        <surname>Pesce</surname>
                        <given-names>A</given-names>
                    </string-name>, <string-name>
                        <surname>Cassuto</surname>
                        <given-names>JP</given-names>
                    </string-name> <article-title>Visceral leishmaniasis associated with Wegener
                        disease. Use of lipid complex amphotericin B and liposomal amphotericin B.</article-title><source>Presse Med</source>
                        <year>1999</year>;<volume>28</volume>:<fpage>959</fpage>&#x2013;<lpage>61</lpage><pub-id pub-id-type="pmid">10366930</pub-id></mixed-citation>
      </ref>
      <ref id="R8">
        <label>8. </label>
        <mixed-citation publication-type="journal"><string-name>
                        <surname>Vardy</surname>
                        <given-names>DA</given-names>
                    </string-name>, <string-name>
                        <surname>Cohen</surname>
                        <given-names>A</given-names>
                    </string-name>, <string-name>
                        <surname>Kachko</surname>
                        <given-names>L</given-names>
                    </string-name>, <string-name>
                        <surname>Zvulunov</surname>
                        <given-names>A</given-names>
                    </string-name>, <string-name>
                        <surname>Frankenburg</surname>
                        <given-names>S</given-names>
                    </string-name> <article-title>Relapse of cutaneous leishmaniasis in a patient
                        with an infected subcutaneous rheumatoid nodule.</article-title><source>Br J Dermatol</source>
                        <year>1999</year>;<volume>141</volume>:<fpage>914</fpage>&#x2013;<lpage>7</lpage>
                        <pub-id pub-id-type="doi">10.1046/j.1365-2133.1999.03169.x</pub-id><pub-id pub-id-type="pmid">10583179</pub-id></mixed-citation>
      </ref>
      <ref id="R9">
        <label>9. </label>
        <mixed-citation publication-type="journal"><string-name>
                        <surname>Sirianni</surname>
                        <given-names>MC</given-names>
                    </string-name>, <string-name>
                        <surname>Barbone</surname>
                        <given-names>B</given-names>
                    </string-name>, <string-name>
                        <surname>Monarca</surname>
                        <given-names>B</given-names>
                    </string-name>, <string-name>
                        <surname>Nanni</surname>
                        <given-names>M</given-names>
                    </string-name>, <string-name>
                        <surname>Lagana</surname>
                        <given-names>B</given-names>
                    </string-name>, <string-name>
                        <surname>Aiuti</surname>
                        <given-names>F</given-names>
                    </string-name> <article-title>A case of Beh&#xE7;et&#x2019;s disease
                        complicated by visceral leishmaniasis and myelodysplasia: clinical
                        considerations.</article-title><source>Haematologica</source>
                        <year>2001</year>;<volume>86</volume>:<fpage>1004</fpage>&#x2013;<lpage>5</lpage><pub-id pub-id-type="pmid">11532637</pub-id></mixed-citation>
      </ref>
      <ref id="R10">
        <label>10. </label>
        <mixed-citation publication-type="journal"><string-name>
                        <surname>Baixauli Rubio</surname>
                        <given-names>A</given-names>
                    </string-name>, <string-name>
                        <surname>Rodriguez Gorriz</surname>
                        <given-names>E</given-names>
                    </string-name>, <string-name>
                        <surname>Campos Fernandez</surname>
                        <given-names>J</given-names>
                    </string-name>, <string-name>
                        <surname>Calvo Catala</surname>
                        <given-names>J</given-names>
                    </string-name>, <string-name>
                        <surname>Garcia Vicente</surname>
                        <given-names>S</given-names>
                    </string-name> <article-title>Enfermedad oportunista poco frecuente en enfermo
                        tratamiento immunosupresor por arthritis reumatoide. </article-title>.
                        <source>Anales de Medicina Interna (Madrid)</source>
                        <year>2003</year>;<volume>20</volume>:<fpage>276</fpage>&#x2013;<lpage>7</lpage></mixed-citation>
      </ref>
      <ref id="R11">
        <label>11. </label>
        <mixed-citation publication-type="journal"><string-name>
                        <surname>Scatena</surname>
                        <given-names>P</given-names>
                    </string-name>, <string-name>
                        <surname>Messina</surname>
                        <given-names>F</given-names>
                    </string-name>, <string-name>
                        <surname>Gori</surname>
                        <given-names>S</given-names>
                    </string-name>, <string-name>
                        <surname>Ruocco</surname>
                        <given-names>L</given-names>
                    </string-name>, <string-name>
                        <surname>Vignali</surname>
                        <given-names>C</given-names>
                    </string-name>, <string-name>
                        <surname>Menichetti</surname>
                        <given-names>F</given-names>
                    </string-name>, <etal/><article-title>Visceral leishmaniasis in a patient treated for polyarteritis
                        nodosa.</article-title><source>Clin Exp Rheumatol</source>
                        <year>2003</year>;<volume>21</volume>(<issue>S32</issue>):<fpage>S121</fpage>&#x2013;<lpage>3</lpage><pub-id pub-id-type="pmid">14740438</pub-id></mixed-citation>
      </ref>
      <ref id="R12">
        <label>12. </label>
        <mixed-citation publication-type="journal"><string-name>
                        <surname>Sollima</surname>
                        <given-names>S</given-names>
                    </string-name>, <string-name>
                        <surname>Corbellino</surname>
                        <given-names>M</given-names>
                    </string-name>, <string-name>
                        <surname>Piolini</surname>
                        <given-names>R</given-names>
                    </string-name>, <string-name>
                        <surname>Calattini</surname>
                        <given-names>S</given-names>
                    </string-name>, <string-name>
                        <surname>Imparato</surname>
                        <given-names>S</given-names>
                    </string-name> <article-title>Visceral leishmaniasis in a patient with
                        Wegener&#x2019;s granulomatosis.</article-title><source>Rheumatology</source>
                        <year>2004</year>;<volume>43</volume>:<fpage>935</fpage>&#x2013;<lpage>7</lpage>
                        <pub-id pub-id-type="doi">10.1093/rheumatology/keh220</pub-id><pub-id pub-id-type="pmid">15213342</pub-id></mixed-citation>
      </ref>
      <ref id="R13">
        <label>13. </label>
        <mixed-citation publication-type="journal"><string-name>
                        <surname>Kon&#xE9;-Paut</surname>
                        <given-names>I</given-names>
                    </string-name>, <string-name>
                        <surname>Retornaz</surname>
                        <given-names>K</given-names>
                    </string-name>, <string-name>
                        <surname>Garnier</surname>
                        <given-names>JM</given-names>
                    </string-name>, <string-name>
                        <surname>Bader-Meunier</surname>
                        <given-names>B</given-names>
                    </string-name> <article-title>Visceral leishmaniasis in a patient with systemic
                        juvenile arthritis treated by IL-1RA agonist (anakinra).</article-title><source>Clin Exp Rheumatol</source>
                        <year>2007</year>;<volume>25</volume>:<fpage>119</fpage><pub-id pub-id-type="pmid">17418007</pub-id></mixed-citation>
      </ref>
      <ref id="R14">
        <label>14. </label>
        <mixed-citation publication-type="journal"><string-name>
                        <surname>Venizelos</surname>
                        <given-names>I</given-names>
                    </string-name>, <string-name>
                        <surname>Tatsiou</surname>
                        <given-names>Z</given-names>
                    </string-name>, <string-name>
                        <surname>Papathomas</surname>
                        <given-names>TG</given-names>
                    </string-name>, <string-name>
                        <surname>Orazi</surname>
                        <given-names>A</given-names>
                    </string-name> <article-title>Visceral leishmaniasis in a rheumatoid arthritis
                        patient treated with methotrexate.</article-title><source>Int J Infect Dis</source> <year>2008</year>; <comment>epub ahead of
                        print</comment><pub-id pub-id-type="pmid">19026580</pub-id></mixed-citation>
      </ref>
      <ref id="R15">
        <label>15. </label>
        <mixed-citation publication-type="journal"><string-name>
                        <surname>Cush</surname>
                        <given-names>JJ</given-names>
                    </string-name> <article-title>Biological drug use: US perspectives on
                        indications and monitoring.</article-title><source>Ann Rheum Dis</source>
                        <year>2005</year>;<volume>64</volume>:<fpage>iv18</fpage>&#x2013;<lpage>23</lpage>
                        <pub-id pub-id-type="doi">10.1136/ard.2005.042549</pub-id><pub-id pub-id-type="pmid">16239379</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
